University Medical School of Naples Federico II,
Dept of Neuroscience,
Reproductive Science and Odontostomatology.
Andrea de Bartolomeis
Via Pansini 5 80131 Napoli Italia,
Edificio 18 Terzo piano, Italy.
Schizophrenia pathophysiology and treatment Antipsychotics Treatment Resistant Schizophrenia Brain gene expression
- Andrea de Bartolomeis MD, Ph.D. is Associate Professor of Psychiatry ad Chief of the Laboratory of Molecular Psychiatry at Department of Neuroscience, University School of Medicine of Napoli Federico II
- Andrea de Bartolomeis received his medical degree and his residency training in psychiatry at the University of Naples Federico II, Italy.
- He completed his postdoctoral fellowship in psychopharmacology and molecular pathophysiology of schizophrenia with NIMH in Bethesda MD (USA) at Clinical Neuroscience Branch (1989-1992) and at Experimental Therapeutics Branch (1993-1995) where he contributed to develop a novel method for quantitation of synaptic dopamine in vivo in primates, using PET and microdialysis simultaneously. This method was instrumental for the first demonstration in vivo by PET and 11C-raclopride of enhanced release of dopamine after amphetamine challenge in striatum of schizophrenics patients compared to normal controls.
- He has been Visiting scientist at Neuroendocrinology Branch of NIMH, Bethesda, MD, USA
- In 1998 he received from the University of Naples a Ph.D. degree in Methodology of Communication Science.
- He is the Head of the Outpatient Clinics for Treatment Resistant Psychosis. and coordinator of the Consultation Psychiatry and Psychotherapy section at Department of Neuroscience and Behavior, University of Naples Federico II. From 2010 he is the director of the Residency program in Psychiatry
- The research interest of Andrea de Bartolomeis includes: molecular pathophysiology of psychosis, CNS gene expression modulation by psychotropic drugs, and augmentation strategy in psychosis pharmacotherapy.
- He has been principal investigator or co-investigator on several research and training grants as well on clinical trials from public and drug company sources.
- He is member of the American Society for Neuroscience, International Society for Schizophrenia Research, New York Academy of Sciences, Italian Society of Neuroscience, Italian Society of Psychopathology.
- He has been elected in the board of directors of the Italian Society for Neuroscience for the years 2012-2016. and board of Italian Chapter of The International Society for Bipolar Disorders
- His curriculum vitae is listed in MarquiÃ¢â‚¬â„¢s Who is Who in Science and Engineering.
- He has authored articles, book chapters, and published abstracts on molecuar mechanisms of antipsychotics as well as on schizophrenia pathophysiology and molecular imaging of dopaminergic system
- He published his works in: Nature Medicine, Proceedings of National Academy of Sciences, Biological Psychiatry, Neuropsychopharmacology, Molecular Brain Research, Synapse, Cerebral Blood flow and Metabolism, Neuroreport, Current Drug Design, European Neuropsychopharmacology, Annals of New York Academy of Sciences, Neuroscience, Molecular Neurobiology, Psychiatry Research. Psychopharmacology, European Neuropsychopharmacology. Journal of Psychiatry Research
- His recent research is focusing on antipsychotics impact on postsynaptic density scaffolding proteins and molecular mechanisms of antipsychotics action as well as on clinical implication of functional neuro-anatomy of treatment -resistant schizophrenia. A novel strategy based on network profiling in silico experiments and molecular imaging gene expression analysis has been developed to better define the multimodal action of antipsychotics.
- The role of Homer protein has been described in multiple animal model of D2R blockade /occupancy, suggesting a role for this gene in antipsychotic mechanism of action and motor side effects.
- The clinical research of Andrea de Bartolomeis is focused on the characterization and functional underpinnings of antipsychotics response and on the profiling of treatment resistant psychosis.